Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

25,526 signal articles · 28 in last 24h · 122,310 total before filter · latest 1h ago
28last 24h
1247last 7d
210● bullish (7d)
149● bearish (7d)
205publishers
AllMacro209Earnings429M&A97Regulatory24Product9Analyst10
✕ clear all filterssentiment: bullishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Bloomberg50d agobullish
Small Hedge Funds Beat Multistrats in Rollercoaster First Half

(Bloomberg) -- Equities and event-driven strategies led hedge-fund gains in the first half of the year, after a brutal first quarter gave way to a broad recovery in recent months.Most Read from BloombergExxon to Change Name for First Time in Decades After RedomicileWhy the Great American State Fair Looks So EmptyGermany Rejects Trump’s Demands for NATO Loyalty to WashingtonRussia Indicates Ukraine Fired Long-Range Ballistic MissileMeta Is Planning a Cloud Business to Sell AI Computing PowerCastl

3 iShares ETFs to Buy Now as South Korea and Taiwan Soar Past 100% Gains in 2026
24/7 Wall St.50d agobullish
3 iShares ETFs to Buy Now as South Korea and Taiwan Soar Past 100% Gains in 2026

The 2026 rally in North Asian equities has been led by the two countries that fabricate the world’s most advanced semiconductors. The iShares MSCI South Korea ETF (NYSEARCA:EWY) is up 103% year to date, the iShares MSCI Taiwan ETF (NYSEARCA:EWT) is up 67%, and the broader iShares Asia 50 ETF (NASDAQ:AIA) has returned 43%. All ... 3 iShares ETFs to Buy Now as South Korea and Taiwan Soar Past 100% Gains in 2026

Vertex Pharmaceuticals (VRTX) Wins FDA Approval To Treat Two Year Olds With CASGEVY
Simply Wall St.50d agobullish
Vertex Pharmaceuticals (VRTX) Wins FDA Approval To Treat Two Year Olds With CASGEVY

FDA approved expanded use of CASGEVY for children as young as two years with sickle cell disease and transfusion-dependent beta thalassemia. The approval makes CASGEVY the first gene therapy of its kind available to this pediatric group in the U.S. Vertex Pharmaceuticals estimates that roughly 5,500 additional children in the U.S. may now be eligible for this one-time genetic treatment. Vertex Pharmaceuticals, traded as NasdaqGS:VRTX, now has FDA approval to offer CASGEVY to a much younger...

Forget Hewlett Packard Enterprise: 1 Dividend-Rich Tech Giant to Buy Hand Over Fist on the Structural Pivot
24/7 Wall St.50d agobullish
Forget Hewlett Packard Enterprise: 1 Dividend-Rich Tech Giant to Buy Hand Over Fist on the Structural Pivot

Wall Street is drooling over Hewlett Packard Enterprise (NYSE:HPE) because the Juniper Networks deal detonated a 148.2% Networking revenue surge in the most recent quarter and management just yanked FY26 EPS guidance to $3.35 to $3.45 from a prior $2.25 to $2.45. But here’s what you should actually be watching. The HPE Story Is a ... Forget Hewlett Packard Enterprise: 1 Dividend-Rich Tech Giant to Buy Hand Over Fist on the Structural Pivot

COIN Vs. MSTR: Buy Coinbase for Pure Exchange Fees and Structural Infrastructure Moats
24/7 Wall St.50d agobullish
COIN Vs. MSTR: Buy Coinbase for Pure Exchange Fees and Structural Infrastructure Moats

Coinbase (NASDAQ:COIN) and Strategy (NASDAQ:MSTR) both reported Q1 2026 results into a brutal crypto tape. Coinbase runs a fee-based crypto exchange with a growing subscription layer. Strategy is a leveraged bitcoin treasury wrapped around a shrinking software business. Same macro, very different machines. Exchange Fees Cushion Coinbase. Bitcoin Marks Break Strategy. Coinbase posted revenue of ... COIN Vs. MSTR: Buy Coinbase for Pure Exchange Fees and Structural Infrastructure Moats

Price Prediction: Up 90% YTD, Will Credo’s Rally Continue?
24/7 Wall St.50d agobullish
Price Prediction: Up 90% YTD, Will Credo’s Rally Continue?

After a 89% year-to-date rally that has taken shares from $143.89 to $271.95, Credo Technology Group (NASDAQ: CRDO) has become one of the most talked-about AI infrastructure plays on the market. Our 24/7 Wall St. price target for Credo is $248.61, implying -8.58% downside over the next 12 months. Our recommendation is hold, with a ... Price Prediction: Up 90% YTD, Will Credo’s Rally Continue?

Wall Street Bulls Look Optimistic About Vertex (VRTX): Should You Buy?
Zacks50d agobullish
Wall Street Bulls Look Optimistic About Vertex (VRTX): Should You Buy?

According to the average brokerage recommendation (ABR), one should invest in Vertex (VRTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Is Caterpillar (CAT) a Buy as Wall Street Analysts Look Optimistic?
Zacks50d agobullish
Is Caterpillar (CAT) a Buy as Wall Street Analysts Look Optimistic?

Based on the average brokerage recommendation (ABR), Caterpillar (CAT) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Is RTX (RTX) a Buy as Wall Street Analysts Look Optimistic?
Zacks50d agobullish
Is RTX (RTX) a Buy as Wall Street Analysts Look Optimistic?

Based on the average brokerage recommendation (ABR), RTX (RTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

These Investors Say Buy Meta Platforms (META) and Ignore SpaceX Hype
Insider Monkey50d agobullish
These Investors Say Buy Meta Platforms (META) and Ignore SpaceX Hype

We just covered Avoid SpaceX and Buy These 11 Stocks Instead. Meta Platforms (NASDAQ:META) ranks #2 (see Avoid SpaceX and Buy These 5 Stocks Instead). Number of Hedge Fund Investors: 262 Meta Platforms (NASDAQ:META) is down about 17% so far this year amid fears that Mark Zuckerberg’s AI spending spree might not result in returns. […]